Antimetastatic activity of the new platinum analog [Pt(cis-dach) (DPPE).2NO3] in a metastatic model of human bladder cancer.

Abstract

Surgical orthotopic implantation (SOI) of histologically intact human RT-4 bladder tumor tissue in nude mice resulted in local growth, invasion, regional extension and metastases as well as distant metastases to other organ sites and lymph nodes, thus mimicking the bladder cancer patient. This metastatic bladder tumor animal model was treated with two doses of new platinum analog ¿Pt(cis-dach)(DPPE).2NO3¿ for the evaluation of antimetastatic efficacy compared to two doses of cisplatinum. Unlike the untreated control group or the group treated with the low dose of cisplatinum, there were no metastases in either the high or low-dose platinum-analog-treated groups and the high-dose cisplatinum-treated group. The results obtained with this patient-like nude-mouse model of bladder cancer indicate that the new platinum analog appears to be a valuable lead compound with antimetastatic efficacy and clinical potential.

• Authors: S G Chang, J I Kim, J C Jung, Y S Rho, K T Lee, Z An, X Wang, R M Hoffman
• Journal: Anticancer research (Anticancer Res) 1997 Sep-Oct Vol. 17 Issue 5A Pg. 3239-42 ISSN: 0250-7005 [Print] Greece
• PMID: 9413154 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• (1,2-bis(diphenylphosphino)ethane)(cis-1,2-diaminocyclohexane)platinum(II)
• Cisplatin

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Cisplatin (therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Humans
• Male
• Mice
• Mice, Nude
• Neoplasm Metastasis
• Organoplatinum Compounds (therapeutic use)
• Tumor Cells, Cultured
• Urinary Bladder Neoplasms (drug therapy)